Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of anti-human BCMA T cells injection in relapsed/refractory multiple myeloma
CTR20221684Phase 2Active
- Sponsor
- Hengrun Dasheng
- Start
- Aug 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of HRC0202 in multiple myeloma (MM), sponsored by Hengrun Dasheng. Started Aug 2022; status: active.
02
Drugs
HRC0202
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20221684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221684.